Good point Adam, that’s how significantly undervalued IHL is.The...

Good point Adam, that’s how significantly undervalued IHL is.

The only other company in the space that has 4 clinical trials planned is BDA and they are capped today at $85 million which is about 5 times that of IHL.

Interestingly their 4 trials relate to skin conditions such as psoriasis, acne and eczema.

I might just point out that one of AXIM’s more advanced products is a cream for psoriasis and dermatitis. Given that IHL have recently announced they have exclusivity over AXIM’s products for 3 years if I were them I’d be looking at that as the next product offering.

Ted